A Pilot Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2017
At a glance
- Drugs 18F-F-AraG (Primary)
- Indications Head and neck cancer
- Focus Biomarker; Pharmacodynamics
- Sponsors CellSight Technologies
- 08 Nov 2017 According to a CellSight Technologies media release, in cohort 1 of the trial 20 patients will be recruited. This trial is led by John Sunwoo, Quynh-Thu Le, Olivier Gaevert ,Chris Holsinger, Nancy Fischbein and Shyam Srinivas.
- 08 May 2017 Status changed from not yet recruiting to recruiting.
- 01 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 May 2017.